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Background: Refractory chronic migraine affects approximately 4% of the population worldwide and 
results in severe pain, lifestyle limitations, and decreased quality of life. Occipital nerve stimulation (ONS) 
refers to the electric stimulation of the distal branches of greater and lesser occipital nerves; the surgical 
technique has previously been described and has demonstrated efficacy in the treatment of a wide 
variety of headache disorders.
Objectives: The aim of this study is to evaluate the long-term efficacy and tolerability of ONS for 
medically intractable chronic migraine.
Study Design: Prospective, long-term, open-label, uncontrolled observational study.
Setting: Single public university hospital.
Methods: Patients who met the International Headache Society criteria for chronic migraine, all of them 
having been previously treated with other therapeutic alternatives, and who met all inclusion and exclusion 
criteria for neurostimulation, received the implantation of an ONS system after a positive psychological 
evaluation and a positive response to a preliminary occipital nerve blockage. The implantation was performed 
in 2 phases: a 10 day trial with implanted occipital leads connected to an external stimulator and, if more 
than 50% pain relief was obtained, permanent pulse generator implantation and connection to the previously 
implanted leads. After the surgery, the patients were thoroughly evaluated annually using different scales: 
pain Visual Analogue Scale  (VAS), number of migraine attacks per month, sleep quality, functionality in social 
and labor activities, reduction in pain medication, patient satisfaction, tolerability, and reasons for termination. 
The average follow-up time was 9.4 ± 6.1 years, and 31 patients completed a 7-year follow-up period.
Results: Thirty-seven patients were enrolled and classified according to the location and quality of their pain, 
accompanying symptoms, work status, and psychological effects. Substantial pain reduction was obtained 
in most patients, and the VAS decreased by 4.9 ± 2.0 points. These results remained stable over the follow-
up period. Five of the 35 permanently implanted patients with migraine attacks at baseline were free from 
these attacks at their last visits, whereas the pain severity decreased 3.8 ± 2.5 (according to the VAS) in 
the remaining patients. Seven of the 35 permanent implanted devices were definitively removed: 2 devices 
because of treatment inefficacy, and 5 devices because the patients were asymptomatic and considered to be 
cured from their pain, even with the stimulation off. Systemic side effects were not observed.
Limitations: Limitations of the current study include its uncontrolled and open-label design. 
Additionally, not all patients completed the 7-year follow-up period.
Conclusions: We consider that the trigemino-cervical autonomous and cervical connection may explain 
why ONS might relieve chronic migraine pain, but this is just a theoretical explanation which should be 
demonstrated in future studies. The results achieved in this study suggest that ONS may provide long-
term benefits for patients with medically intractable chronic migraine. These outcomes are slightly better 
than previous reports and were maintained over the 7-year follow-up. We believe that an accurate 
selection of patients, realization of diagnostic occipital nerve blocks, psychological evaluations, rigorous 
surgical technique, and appropriate parameter programming helped us achieve these outcomes. 
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poor responses (i.e., an absence of efficacy or the pres-
ence of important adverse events). The exclusion cri-
teria included pregnancy, age younger than 18 years 
or older than 80 years, structural lesions (identified by 
brain imaging), underlying disorders capable of caus-
ing headache, medication overuse, and informed con-
sent refusal. Additionally, all patients met the following 
inclusion criteria: integrity of the nerve structures that 
require stimulation, willingness and ability to manage 
the neurostimulation devices, and absence of other im-
planted electrical stimulation devices. All patients un-
derwent a psychological evaluation to rule out other 
psychiatric disorders and to confirm that they would be 
able to accept the device implantation. All procedures 
were performed with ethical approval from our institu-
tional review board, and written consent was obtained 
from all patients.
Prior to the ONS implantation, a preliminary oc-
cipital nerve blockage was performed with a local an-
esthetic (lidocaine 1%, svedocain 0.25%), and only the 
patients who demonstrated good responses (at least 
50% relief according to the visual analogue scale [VAS]) 
were selected for permanent ONS. 
The first phase included subcutaneous electrode 
placement at the cervical/occipital junction at the ex-
tracranial exit of the greater and lesser occipital nerves, 
according the technique first described by Popeney and 
Aló in 2003 (14). A 15 G Tuohy needle was introduced 
in a subcutaneous plane above the muscular fascia from 
the midline of C1 in the direction of the mastoid. The 
electrode was inserted, and an intraoperative exter-
nal stimulation test was performed in order to achieve 
pleasant paresthesia spreading at least 10 cm along 
the occipital nerve(s). In order to avoid discomfort or 
pain commonly associated with lead anchoring ele-
ments implanted at high dorsal or cervical levels, leads 
were fixated to the muscular fascia with silk suture by 
means of several crosses and knots applied around the 
lead, in the same way as with Redon drains (Fig. 1). In 
all patients, electrode placements were radiologically 
controlled (Fig. 2).
Patients were evaluated after an average period of 
10 days, and only those with a greater than 50% de-
crease in VAS were selected for the permanent implant. 
Since 2007, all patients have been implanted with dou-
ble sets of leads, regardless of their uni- or bilateral 
pain distribution, after the potential complications of 
single occipital lead use were described (15).
The permanent system implantation was per-
formed in a second surgical phase. The leads were kept 
Refractory chronic migraine (RCM) affects approximately 4% of the population worldwide and results in severe pain, lifestyle limitations, 
and decreased quality of life. It also affects the quality 
and quantity of an individual’s work and results in a 
significant economic burden (1,2). Although a number 
of treatments have been approved to treat chronic 
migraine, there are still many patients suffering from 
RCM; thus, other treatments are warranted.
Occipital nerve stimulation (ONS) was initially in-
troduced in 1999 as a therapeutic option to treat pain 
in refractory patients (3). Although its utility was first 
described in several small studies, larger studies have 
been published, and ONS has demonstrated efficacy in 
the treatment of a wide variety of headache disorders, 
such as chronic and episodic migraine, cluster head-
ache, occipital neuralgia, trigeminal neuralgia, hemi-
crania continua, and posttraumatic headache (4-6). Fur-
thermore, this technique appears to be safe and well 
tolerated by patients; therefore, the number of treated 
patients is rapidly increasing. ONS refers to the electric 
stimulation of the distal branches of greater and lesser 
occipital nerves by means of fixed-frequency electric 
pulses; the surgical technique has previously been de-
scribed (7-9). 
Recently, other neurostimulation techniques have 
emerged as promising treatments for patients with 
disabling and intractable headaches. An increasing 
number of studies have suggested that several nerves 
could be used as a therapeutic target to treat headache 
disorders, such as the occipital, vagus, sphenopalatine 
ganglion, and supraorbital nerves (10-12). New non-
invasive devices that target these peripheral structures 
are under development, and the initial experiences 
have been described. However, long-term studies re-
main scarce.
The aim of this study is to evaluate the long-term 
efficacy and tolerability of ONS for medically intracta-
ble chronic migraine.
Methods
After having been diagnosed and referred to 
our unit by the hospital’s Neurology Service, patients 
who met the International Headache Society criteria 
(13) for chronic migraine were included in this study. 
Although these criteria were published in 2004, all of 
them were also valid for patients previously enrolled 
in our study. All patients had been previously treated 
with other therapeutic alternatives, such as pharma-
cological drugs, denervation, or physiotherapy, with 
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Fig. 1. Anchoring technique.
Fig. 2. Suboccipital subcutaneous placement of  the bilateral four-pole leads.
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in place after the trial, and only the intermediate exten-
sion was replaced during the final implantation of the 
pulse generator.
The following stimulation devices were used, with 
the corresponding extension cables: Pisces Quad and 
Octad percutaneous leads and Itrel 3, Synergy, Syner-
gy Versitrel, and Prime Advanced pulse generators (all 
from Medtronic Inc., Minneapolis, MN, USA). One pa-
tient was initially implanted with a surgical quadripo-
lar plate lead (Resume, Medtronic); however, effective 
paresthesia could not be attained, and the lead was 
replaced by a percutaneous lead. The patients were al-
lowed to continue analgesics and other medications for 
migraine, including abortive and preventive therapies.
The stimulator was programmed to create a pleas-
ant paresthetic sensation spreading throughout the oc-
cipital region. After seeking the best polarity combina-
tion (usually one or 2 bipoles in each stimulation lead), 
initial parameter programming was performed at 40 Hz 
pulse frequency and 250 µs pulse width. Perception and 
discomfort pulse amplitude limits were fixed and the 
patients were taught to handle their patient program-
mers. Regardless of the uni- or bilateral migraine symp-
toms, since 2007 all patients were stimulated bilater-
ally, either with a single stimulation program or – if left 
and right stimulation thresholds differed significantly 
– independent stimulation by means of 2 simultaneous 
programs. During the follow-up, voltage values were 
modified when necessary to adapt to threshold chang-
es, and pulse frequencies and widths were set to regu-
late the paresthesia quality and coverage respectively.
After the ONS surgery, the patients were thor-
oughly evaluated annually using different scales: the 
VAS, number of migraine attacks per month, sleep 
quality (normal, bad, very bad), functionality in social 
and labor activities (%), reduction in pain medication 
(including abortive and preventive drugs), patient sat-
isfaction (very satisfied, satisfied, neither satisfied nor 
unsatisfied, unsatisfied, very unsatisfied), tolerability, 
and reasons for termination. 
Results
Forty-one consecutive patients diagnosed with 
CRM by our hospital’s Neurology Service and referred 
to our pain unit were initially selected for ONS. In 4 pa-
tients (one man, 3 women) the diagnostic nerve block 
did not produce significant relief so they were excluded 
from the study.
Thirty-seven patients (4 men and 33 women) were 
finally enrolled. All surgical and follow-up procedures 
were performed in Zaragoza Universitary Hospital be-
tween June 2002 and June 2013. The average patient 
age was 46.9 ± 10.4 years (range, 27 – 74 years); the 
pain primarily affected different areas: frontal (86%), 
parietal (83%), temporal (80%), retroocular and facial 
(58%), and supraclavicular (14%). Thirty-five patients 
(95%) suffered continuous pain (mean VAS, 5.5 ± 1.8), 
whereas 36 patients had sporadic migraine seizures 
(mean VAS, 9.1 ± 0.64). The only 2 patients without 
continuous pain suffered from severe migraine attacks 
(mean VAS, 10.0 ± 0.0). The only patient without mi-
graine seizures scored 7 on the VAS. The patients de-
scribed pain as oppressive (92%) and pulsating (68%), 
and some patients also reported photophobia or pho-
nophobia (71%), nausea (68%), vascular symptoms 
(46%), dysesthesia (30%), allodynia (30%), itching 
(24%) and paresthesia (22%), swelling (22%), vertigo 
(16%), and trigeminal pain (5%). Twenty-four of the 37 
patients were working, and 17 patients (72%) reported 
decreased productivity. Twenty-seven patients (73%) 
were depressed. 
Only one of the 37 patients selected for ONS did 
not demonstrate a good response in the first phase 
of the study; thus, he did not undergo the permanent 
implantation. This patient had unilateral right pain 
without an extra-cranial component and had been im-
planted with a single quadripolar percutaneous lead. 
The other 36 patients were implanted with permanent 
systems (Table 1).
The average follow-up time was 9.4 ± 6.1 years, 
and 31 patients completed a 7-year follow-up period.
Substantial pain reduction was obtained in most 
patients, and the VAS decreased by 4.9 ± 2.0 points. 
These results remained stable over the entire follow-up 
period (Fig. 3). Five of the 35 permanently implanted 
patients with migraine attacks at baseline were free 
from these attacks at their last visits, whereas the pain 
severity decreased 3.8 ± 2.5 (according to the VAS) in 
the remaining patients.
The number of migraine days per month also de-
creased from 17.9 ± 0.1 at baseline to 7.3 ± 7.2 at the 
last visit, and no important differences were identified 
throughout the 7-year follow-up period.
Thirty-one of the 35 patients experienced a greater 
than 50% reduction in migraine frequency, whereas 
this decrease was less than 50% in 3 patients; only one 
of the 35 patients did not obtain any relief. Three pa-
tients with limited responses in migraine severity ob-
tained an important decrease in migraine frequency.
Other symptoms also improved after the ONS 
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treatment (Fig. 4). Vertigo disappeared in 6 of 6 pa-
tients who suffered from it at baseline, and vascular 
symptoms also disappeared in 15 of 16 patients. The 
only patient who reported continued edema during his 
seizures was the same patient who demonstrated no 
response after the ONS treatment.
Family and social activities also substantially im-
proved after treatment and remained stable over the 
7-year follow-up period. Social activities changed from 
64.4 ± 21.6% at baseline to 95.3 ± 12.3%, whereas 31 
patients scored 100%. Following on from this subject, 4 
patients changed from 37.5% to 65% (average values), 
and one patient did not demonstrate any improvement 
in this respect. In terms of work, 14 of 17 patients re-
turned to their jobs.
Sleep quality also improved and remained stable 
over the 7-year follow-up period. At baseline, the sleep 
quality was considered normal for only 3 patients, bad 
for 25 patients (71%), and very bad for 7 patients (20%). 
However, at the last visit, the sleep quality changed to 
normal in 32 patients (91%), and only 3 patients contin-
ued to report bad or very bad sleep quality.
Concomitant oral medication use was also re-
duced. The average number of concomitant drugs was 
reduced from 4.4 ± 1.7 at baseline to 1.3 ± 1.6 at the last 
follow-up visit. Fourteen patients (40%) did not take 
any analgesic medications.
The ONS treatment was generally well tolerated. 
Two patients complained of painful stimulation, which 
was solved by reprogramming. There were 4 cases of 
lead externalization. In one case, the explanted lead 
was contralateral to the pain, and it was not re-im-
planted because the patient continued to significantly 
improve. In the other 3 patients, the whole system was 
Pain Distribution N Lead Configuration Permanent Generator















Table 1. Pain distribution and type of  permanent implants.
Fig. 3. Pain severity evolution according to the AVS during the 7-year follow-up period.
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explanted, one because of inefficacy and 2 because the 
patients were asymptomatic and reported significant 
pain relief without stimulation after 4 and 8 years of 
treatment. In one patient, there was a lead migration 
during the test phase, and the lead was surgically relo-
cated during the permanent implantation.
There were 3 cases of infection, which all occurred 
in the generator pocket. One lead was surgically re-
placed; in the other 2 cases, the complete system was 
explanted because the patients were considered to be 
cured after 4 and 8 years of treatment.
Seven of the 35 permanent implanted devices were 
definitively removed: 2 devices were removed because 
of treatment inefficacy, and 5 devices were removed be-
cause the patients were asymptomatic and considered 
to be cured from their pain, even with the stimulation 
off. Systemic side effects were not observed.
During the entire follow-up, 2 implanted genera-
tors reached their end-of-life and required replace-
ment: one Synergy was replaced after 8 years, and one 
Versitrel was replaced after 3 years of lifetime service. 
This unusually long service lifetime is likely because of 
the low energy requirements, particularly the daily us-
age time of the system. See Table 2 for programming 
Fig. 4. Changes in the main scorings from baseline to the last follow-up visit.
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and usage details.
discussion
The results of this study suggest that ONS may pro-
vide long-term benefits for patients with medically in-
tractable chronic migraine. Most patients experienced 
important improvements in some of the studied areas, 
such as migraine severity, frequency, sleep quality, con-
comitant medication intake, or social or work activities. 
These long-term outcomes are noteworthy, particularly 
because at our institution, only severe and refractory 
patients are referred for ONS, and the results remained 
stable for the entire 7-year follow-up period.
Since this technique was first reported by Weiner 
and Reed in 1999 (3), an increasing number of publica-
tions have confirmed and continue to confirm its use-
fulness in the treatment of chronic migraine and other 
medically intractable headaches. Therefore, the ten-
dency of this treatment modality is towards a progres-
sive increase, both in the number of cases treated and 
its therapeutic possibilities.
Popeney and Aló (14) confirmed the role of ONS in 
the treatment of medically intractable chronic migraine 
in a study of 25 patients over an 18.3-month follow-
up period; 64% of the patients in the study improved 
by at least 50%. Other studies have also demonstrated 
the efficacy and good tolerability of ONS for chronic 
migraine (16-23). 
However, there are few long-term reports of ONS. 
Brewer et al (24) conducted a retrospective review of 
the medical records of 14 patients who were implant-
ed, followed by phone interviews. According to their 
results, ONS was successful in 5 of the 12 migraine pa-
tients, 4 of the 5 patients with cluster headaches, and 5 
of the 8 miscellaneous headache patients. Palmisani et 
al (25) published a 6-year retrospective review of ONS 
for the treatment of different refractory headache syn-
dromes in 25 patients. They also confirmed the long-
term ONS success rate in refractory chronic headaches 
and suggested that some types of headaches may re-
spond better to ONS than other types. To the best of 
our knowledge, our study is the largest study to investi-
gate the long-term efficacy and tolerability of ONS for 
medically intractable chronic migraine. Our results sup-
port the use of ONS as a long-term treatment for these 
patients, as well as the idea that treatment efficacy re-
mains stable throughout the 7-year follow-up period.
The mechanisms of action of peripheral nerve 
stimulation in the treatment of chronic migraine re-
main unknown; the functional trigeminal-cervical 
connection proposed by Bartsch et al and Bartsch and 
Goadsby’s findings (26,27) (Fig. 5) has been described as 
a potential explanation for the pain relief achieved by 
ONS in chronic migraine patients, although of course 
this theory must be proven by other studies. Stimuli on 
trigeminal nociceptors that produce clinical trigeminal 
and cervical responses (and vice versa) may character-
ize the mechanisms of trigemino-cervical convergence 
(28-30).
Another point for discussion is the 2-phase surgery. 
Some studies have reported that a positive response to 
occipital nerve block administered prior to ONS predicts 
a positive response to ONS. However, other studies con-
cerned with proper patient selection have claimed no 
predictive value in blocking the occipital nerve (31,32). 
Although this issue requires further investigation, in 
our study, a prognostic block with a local anesthetic 
was performed in all patients prior to electrode implan-
tation. Therefore, it remains unknown whether occipi-
tal nerve block helped us to better select the patients 
and obtain better results.
The authors of the study are aware that the results 
here described are better than other previously pub-
lished ones. In our opinion, possible causes for this high 
success rate may include a thorough diagnosis made by 
the Neurology Service, psychological evaluation ensur-
ing the patients’ commitment and ability to operate 
the system, diagnostic block to discard non-feasible 
patients, midline technique without anchoring devices, 
and proper programming, discarding when possible 
multipolar configurations and focusing on efficient bi-
pole and tripole combinations.
Limitations of the current study include its uncon-
trolled and open-label design. Additionally, not all pa-
tients completed the 7-year follow-up period. Despite 
Settings/Parameters Average Min Max
Nº Simultaneous Programs 1.45 1 2
Pulse Amplitude (V) 1.89 0.8 3.7
# of Active Cathodes 1.91 1 6
# of Active Anodes 1.36 1 6
Pulse Width (µs) 286.4 210 450
Pulse Frequency (Hz) 43.1 30 60
Daily Usage Time Initial (h) 12.0 2.0 24.0
Daily Usage Time Final (h) 4.4 0.0 8.0
Table 2. Average, minimum and maximum program settings 
and the patient’s use of  the system.
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Fig. 5. Neural pathways involved in the trigeminocervical convergence theory.
these limitations, the findings suggest that ONS could 
be an effective, well-tolerated, long-term treatment for 
medically RCM. Controlled and larger studies are war-
ranted to confirm these results.
conclusion
Although its mechanisms of action still remain 
unclear, the outcomes of this study suggest that ONS 
might be a safe, effective, and sustainable treatment 
for refractory chronic migraine.
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